Download PDF
Am J Perinatol 2001; 18(7): 379-386
DOI: 10.1055/s-2001-18695
ORIGINAL ARTICLES

Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4693

Response to Hepatitis B Vaccine in Preterm Infants: Four-Dose Schedule

Angel Ballesteros-Trujillo1 , Arturo Vargas-Origel2 , Teresa Alvarez-Muñoz3 , Carlos Aldana-Valenzuela1
  • 1Department of Neonatology, Hospital de Gineco-Pediatría No. 48, Instituto Mexicano del Seguro Social, León, Gto., México
  • 2Research Unit in Clinical Epidemiology, Hospital de Gineco-Pediatría No. 48, Instituto Mexicano del Seguro Social, León, Gto., México
  • 3Research Unit in Infectious and Parasitic Diseases, Hospital de Pediatría, Centro México Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México, D.F
Further Information

Publication History

Publication Date:
03 December 2001 (online)

Also available at
    Permissions and Reprints

ABSTRACT

The objective of this study is to test a four-dose Hepatitis B vaccine schedule in premature infants (PI) and assess the immunogenicity of the vaccine with this schedule. We studied 29 PI who received the vaccine against Hepatitis B at birth, 1, 5, and 9 months of age. Antibodies against surface antigen (Anti-HBs) were measured before the third and fourth doses and 12 weeks after the fourth dose. Levels higher than 10 mIU/mL were considered protective, whereas more than 100 mIU/mL was an excellent response. Twenty-nine PI were studied. The average weight at the time of the initial dose was 1398 g, gestational age of 32.5 weeks, and a postnatal age of 9 days. Since the initial measurement, protective levels were achieved in all patients. The response was excellent in 24.1, 75.9, and 89.7%, after the second, third, and fourth doses, respectively. No correlation was found between the type of response and the infants' weight or the postnatal age. The Anti-HBs geometrical levels were 51.9, 133, and 133 mIU/mL after the second, third, and fourth doses, respectively. The favorable results obtained might be due to: the four-dose schedule itself, the dose we used (10 μg), the time interval between the doses, and even a race factor. Our schedule seems to be useful for PI infants and probably is no longer necessary to delay the vaccination, although this should be confirmed by further studies.

KEYWORD

Hepatitis B vaccine - premature infants - new vaccine schedule

REFERENCES

  • 1 Jonas M M, Schiff E F, O'Sullivan M J. Failure of the centers for disease control criteria to identify hepatitis B infection in a large municipal obstetrical population.  Ann Intern Med . 1987;  107 335-337
    PubMedSearch in Google Scholar
  • 2 Alter M J, Haddler S C, Margelis H S. Changing epidemiology of hepatitis B in the United States: need of alternative vaccination strategies.  JAMA . 1990;  263 1218-1222
    CrossrefPubMedSearch in Google Scholar
  • 3 Committee of Infectious Diseases. American Academy of Pediatrics. Universal hepatitis B immunization.  Pediatrics . 1992;  89 795-800
    PubMedSearch in Google Scholar
  • 4 McMahon B J, Rhoades E R, Heyward W L. A comprehensive program to reduce the incidence of hepatitis B infections and its sequelae in Alaskan natives.  Lancet . 1987;  2 1134-1136
    PubMedSearch in Google Scholar
  • 5 Tan K L, Goh K T, Oon C J, Chan S H. Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization.  JAMA . 1994;  271 859-861
    CrossrefPubMedSearch in Google Scholar
  • 6 West D J. Clinical experience with hepatitis B vaccines.  Am J Infect Control . 1989;  17 172-180
    PubMedSearch in Google Scholar
  • 7 Grosheide P M, del Canho R, Heijtink R A. Passive-active immunization in infants of hepatitis B antigen-positive mothers.  AJDC . 1993;  147 1316-1320
    PubMedSearch in Google Scholar
  • 8 Committee of Infectious Diseases. Update of timing of hepatitis B vaccination for premature infants and for children with lapsed immunization.  Pediatrics . 1994;  94 403-404
    PubMedSearch in Google Scholar
  • 9 Lau Y L, Tam A YC, Ng K W. Response of preterm infants to hepatitis B vaccine.  J Pediatr . 1992;  121 962-965
    CrossrefPubMedSearch in Google Scholar
  • 10 Chirico G, Belloni C, Gasparoni A. Hepatitis immunization in infants of hepatitis B surface antigen-negative mothers.  Pediatrics . 1993;  92 717-719
    PubMedSearch in Google Scholar
  • 11 Belloni C, Chirico G, Pistorio A, Orsolini F, Tinelli C, Rondini G. Immunogenicity of Hepatitis B vaccine in term and preterm infants.  Acta Paediatr . 1998;  87 336-338
    CrossrefPubMedSearch in Google Scholar
  • 12 Blondheim D, Bader D, Abend M. Immunogenicity of hepatitis B vaccine in preterm infants.  Arch Dis Child . 1998;  3 F206-F208
    PubMedSearch in Google Scholar
  • 13 Capurro H, Konichezky S, Fonseca D, Caldeyro-Barcia R. A simplified method for diagnosis of gestacional age in the newborn infant.  J Pediatr . 1978;  93 120-122
    PubMedSearch in Google Scholar
  • 14 Patel D M, Butler J, Feldman S, Graves G R, Rhodes P G. Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants.  J Pediatr . 1997;  130 641-643
    PubMedSearch in Google Scholar
  • 15 Dawson-Saunders B, Trapp R G. Bioestadística Médica.  2nd ed. México, D.F.: Manual Moderno 1997: 105-276
    Search in Google Scholar
  • 16 Committee of Infectious Diseases. American Academy of Pediatrics. Report of the committee of infectious disease. In: Peter G, ed. 1997 Red Book, 24th ed. Elk Grove Village, IL: American Academy of Pediatrics 1997: 325-340
    Search in Google Scholar
  • 17 Losonsky G A, Wasserman S S, Stephens I. Hepatitis B vaccination of premature infants: a reassessment of current recommendations of delayed immunization.  Pediatrics . 1999;  103 8-14
    CrossrefPubMedSearch in Google Scholar
  • 18 West D J, Calandra G B, Ellis R W. Vaccination of infants and childrens against hepatitis B.  Pediatr Clin North Am . 1990;  37 585-601
    PubMedSearch in Google Scholar
  • 19 Golebiowska M, Kardas-Sobantka D, Chlebna-Sokol D, Sabanty W. Hepatitis B vaccination in preterm infants.  Eur J Pediatr . 1999;  158 293-297
    CrossrefPubMedSearch in Google Scholar
  • 20 Kim S, Chang E, Hodinka R. Immunogenicity of hepatitis B vaccine in preterm infants.  Pediatrics . 1997;  99 534-536
    CrossrefPubMedSearch in Google Scholar
  • 21 Huang F Y, Lee P I, Huang L M, Chang L Y, Liu S C. Hepatitis B vaccination in preterm infants.  Arch Dis Child . 1997;  77 F135-F138
    PubMedSearch in Google Scholar
  • 22 Tomas H C. The hepatitis B virus and the host response.  J Hepatol . 1990;  11 S83-S89
    PubMedSearch in Google Scholar
  • 23 Landa L. Seroepidemiología de la Hepatitis B.  Gac Med Méx . 1976;  11 85-90
    PubMedSearch in Google Scholar
  • 24 Ortiz-Ibarra F, Lara-Sánchez J, Figueroa-Damián M, Arredondo-García J, Ahued-Ahued J. Prevalencia de marcadores serológicos de los virus de la Hepatitis A, B, C, y D en embarazadas.  Sal Pub Mex . 1996;  38 317-322
    PubMedSearch in Google Scholar
  • 25 Hernández-Arriaga J, Ramírez-Crespo A, De Anda-Gómez M, Castellanos-Martínez J. Marcadores serológicos de Hepatitis B en la etapa perinatal.  Bol Med Hosp Infant Mex . 2000;  57 10-9
    PubMedSearch in Google Scholar